Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-AL1 Study in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis
Shots:
- The P-III TOURMALINE-AL1 (NCT01659658) study involves assessing of Ninlaro + dexamethasone vs dexamethasone + (melphalan/ cyclophosphamide/ thalidomide/ lenalidomide)/ monothx in patients with relapsed or refractory systemic light chain (AL) amyloidosis
- The P-III TOURMALINE-AL1 study resulted in unmet 1EPs as well as demonstrated no improvement in overall hematologic response leading to its discontinuation
- Ninlaro (ixazomib) is an oral proteasome inhibitor currently evaluated in multiple myeloma and is approved in 60+ countries including the US- Japan and EU with 10+ regulatory filings under review
Ref: Takeda | Image:Takeda
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com